Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Patrick Vermersch, Jiwon Oh, Mark Cascione, Celia Oreja-Guevara, Claudio Gobbi, Lori H. Travis, Kjell Morten Myhr, Patricia K. Coyle

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT.

Original languageEnglish (US)
Article number102158
JournalMultiple Sclerosis and Related Disorders
StatePublished - Aug 2020
Externally publishedYes


  • Disease modifying therapies
  • Injectable DMTs
  • Multiple sclerosis
  • Switching
  • Teriflunomide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS'. Together they form a unique fingerprint.

Cite this